Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527703 | 0.73 | — | — | |
| SCHEMBL377823 | 0.73 | LMNA (0.44) | ALDH1A1LMNAMAPK1KDM4E | |
| SCHEMBL377467 | 0.73 | LMNA (0.44) | ALDH1A1LMNAMAPK1KDM4E | |
| SCHEMBL377693 | 0.71 | RAB9A (0.40) | ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL377425 | 0.71 | RAB9A (0.40) | ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL377869 | 0.70 | KDM4E (0.53) | ALDH1A1LMNAMAPK1KDM4E | |
| SCHEMBL1631060 | 0.70 | L3MBTL1 (0.52) | ALDH1A1LMNATSHRMAPK1KDM4E | |
| SCHEMBL9937728 | 0.70 | CTSK (0.37) | HSD11B1 | |
| SCHEMBL1704763 | 0.69 | CYP4F2 (0.38) | ALDH1A1LMNAKDM4E | |
| SCHEMBL3565835 | 0.69 | RAB9A (0.41) | ALDH1A1LMNAPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836763-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200071325-A1 | 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836763-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | JAK1, JAK2, JAK3 | HSD11B1 3192/4885ALDH1A1 2183/4885LMNA 4866/4885 |
| US-20200071325-A1 | 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | HSD11B1 3192/4885ALDH1A1 2183/4885LMNA 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.